| Oct 20, 2009 |
Canada Approves Isentress® For Adults Starting HIV Treatment 
|
| Jul 20, 2009 |
Raltegravir as Effective as Efavirenz at Suppressing HIV Viral Load and Increasing CD4 Cell Counts in Treatment-Naïve Patients Up to 144 Weeks When Used in Combination Therapy
|
| Feb 11, 2009 |
Raltegravir, in Combination with Other HIV Medicines Shown as Effective as Efavirenz in Suppressing Viral Load and Increasing CD4 Cell Counts in Treatment-Naïve HIV-infected Patients with High Levels of Virus, Across Various Populations, in Investigational Study
Phase III Studies Showed Raltegravir in Combination Therapy Provided Significant Viral Load Reductions through 96 Weeks in Treatment-Experienced Patients with Triple-Class Resistant HIV
|
| Feb 11, 2009 |
Data from Raltegravir in Patients Whose HIV is Controlled on a Lopinavir/Ritonavir-Based Therapy Presented at the 16th Conference on Retroviruses and Opportunistic Infections
-Switching from Lopinavir/Ritonavir-Based to Raltegravir-Based Combination Antiretroviral Therapy Significantly Improved Total Cholesterol, Triglycerides, Non-HDL-Cholesterol at Week 12
-Switching from Lopinavir/Ritonavir-Based to Raltegravir-Based Combination Antiretroviral Therapy Did Not Demonstrate Non-Inferior Virologic Efficacy
|
| Nov 24, 2008 |
HIV+25 Survey Asks Where Are we in Canada Twenty-Five Years After Discovery of the Virus
|
|
Oct 26, 2008
|
New Phase III Study in previously untreated HIV patients showed Raltegravir reduced HIV viral load to undetectable levels, comparable to Efavirenz, when taken in combination with other medicines
|
| Oct 7, 2008 |
Innovative HIV-AIDS treatment ISENTRESS™ now available to Canadian First Nations
|
|
August 5, 2008
|
ISENTRESS™ (raltegravir), Merck Frosst's First in Class Integrase Inhibitor, Reduced HIV Viral Load and Increased CD4 Cell Counts. Through 96 Weeks in Treatment-Naïve HIV-Infected Patients
|
|
Nov 30, 2007
|
Health Canada Approves ISENTRESSTM (raltegravir)
Only drug to inhibit Integrase Enzyme
|
| July 24, 2007 |
Raltegravir in Combination Therapy Demonstrates Potent Antiretroviral Activity in Treatment-Naïve HIV-Positive Patients
|
| March 1, 2007 |
Results from Two Phase III Studies on Raltegravir, MK-0518,an Oral Investigational Integrase Inhibitor, Presented at the Annual Conference on Retroviruses and Opportunistic Infections |
